The Department of Biotechnology and its PSU, Biotechnology Industry Research Assistance Council, on Wednesday announced that the Drug Controller General of India had given emergency use authorization for the first-of-its-kind intranasal COVID-19 vaccine developed by Bharat Biotech.
The development of the vaccine was supported by DBT and BIRAC under the aegis of Mission COVID Suraksha. DBT launched the mission, and BIRAC implemented it to reinforce and accelerate COVID-19 vaccine development efforts as part of the Aatmanirbhar 3.0 programme. This is the fourth success story for the COVID-19 vaccine under mission COVID Suraksha.
Named BBV154, it is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vector vaccine. It consists of a replication-deficient ChAd vector expressing the stabilized Spike SARS-CoV-2 (Wuhan variant).
DBT’s Autonomous Institute, National Institute of Immunology (NII), New Delhi, used its Human Immune Monitoring and T-cell Immunoassay platform to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses in the trial participants. Interactive Research School for Health Affairs, Pune, completed the Plaque Reduction Neutralization Assay to quantify the titre of neutralizing antibodies for the virus from three trial sites.
Commenting on the development, Dr. Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, “The Department, through Mission COVID Suraksha, is committed to the development of safe and efficacious COVID-19 vaccines. BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group, for restricted use in an emergency. An excellent example of the Aatmanirbharta initiative of the Government of India. I congratulate our scientists for partnering with Bharat Biotech and supplying scientific leadership throughout the development of the vaccine”. (ISW)
If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook
